Pulmatrix Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.23
- Today's High:
- $2.28
- Open Price:
- $2.28
- 52W Low:
- $2.23
- 52W High:
- $4.66
- Prev. Close:
- $2.28
- Volume:
- 3835
Company Statistics
- Market Cap.:
- $8.33 million
- Book Value:
- 6.42
- Revenue TTM:
- $6.92 million
- Operating Margin TTM:
- -260.02%
- Gross Profit TTM:
- $6.07 million
- Profit Margin:
- -253.24%
- Return on Assets TTM:
- -27.85%
- Return on Equity TTM:
- -56.66%
Company Profile
Pulmatrix Inc had its IPO on 2014-03-21 under the ticker symbol PULM.
The company operates in the Healthcare sector and Biotechnology industry. Pulmatrix Inc has a staff strength of 28 employees.
Stock update
Shares of Pulmatrix Inc opened at $2.28 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.23 - $2.28, and closed at $2.27.
This is a -0.25% slip from the previous day's closing price.
A total volume of 3,835 shares were traded at the close of the day’s session.
In the last one week, shares of Pulmatrix Inc have slipped by -3.22%.
Pulmatrix Inc's Key Ratios
Pulmatrix Inc has a market cap of $8.33 million, indicating a price to book ratio of 0.3832 and a price to sales ratio of 2.7564.
In the last 12-months Pulmatrix Inc’s revenue was $6.92 million with a gross profit of $6.07 million and an EBITDA of $-17857000. The EBITDA ratio measures Pulmatrix Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Pulmatrix Inc’s operating margin was -260.02% while its return on assets stood at -27.85% with a return of equity of -56.66%.
In Q2, Pulmatrix Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 38.5%.
Pulmatrix Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-4.81 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pulmatrix Inc’s profitability.
Pulmatrix Inc stock is trading at a EV to sales ratio of 0.1904 and a EV to EBITDA ratio of 1.5158. Its price to sales ratio in the trailing 12-months stood at 2.7564.
Pulmatrix Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $31.39 million
- Total Liabilities
- $3.60 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $58000
- Dividend Payout Ratio
- 0%
Pulmatrix Inc ended 2024 with $31.39 million in total assets and $0 in total liabilities. Its intangible assets were valued at $31.39 million while shareholder equity stood at $23.45 million.
Pulmatrix Inc ended 2024 with $0 in deferred long-term liabilities, $3.60 million in other current liabilities, in common stock, $-281740000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $25.79 million and cash and short-term investments were $25.79 million. The company’s total short-term debt was $358,000 while long-term debt stood at $0.
Pulmatrix Inc’s total current assets stands at $27.38 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $418000.00 compared to accounts payable of $929000.00 and inventory worth $900000.00.
In 2024, Pulmatrix Inc's operating cash flow was $0 while its capital expenditure stood at $58000.
Comparatively, Pulmatrix Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.27
- 52-Week High
- $4.66
- 52-Week Low
- $2.23
- Analyst Target Price
- $10
Pulmatrix Inc stock is currently trading at $2.27 per share. It touched a 52-week high of $4.66 and a 52-week low of $4.66. Analysts tracking the stock have a 12-month average target price of $10.
Its 50-day moving average was $2.55 and 200-day moving average was $3.11 The short ratio stood at 0.19 indicating a short percent outstanding of 0%.
Around 0.2% of the company’s stock are held by insiders while 1779.4% are held by institutions.
Frequently Asked Questions About Pulmatrix Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.